Cleavage stimulation factor 50 kDa subunit is a protein that in humans is encoded by the CSTF1gene.[1][2][3]
This gene encodes one of three subunits which combine to form cleavage stimulation factor (CSTF). CSTF is involved in the polyadenylation and 3'end cleavage of pre-mRNAs. Similar to mammalian G protein beta subunits, this protein contains transducin-like repeats. Several transcript variants with different 5' UTR, but encoding the same protein, have been found for this gene.[3]
↑Takagaki Y, Manley JL (Dec 1992). "A human polyadenylation factor is a G protein beta-subunit homologue". J Biol Chem. 267 (33): 23471–4. PMID1358884.
↑ 2.02.1Kleiman FE, Manley JL (Mar 2001). "The BARD1-CstF-50 interaction links mRNA 3' end formation to DNA damage and tumor suppression". Cell. 104 (5): 743–53. doi:10.1016/S0092-8674(01)00270-7. PMID11257228.
Murthy KG, Manley JL (1995). "The 160-kD subunit of human cleavage-polyadenylation specificity factor coordinates pre-mRNA 3'-end formation". Genes Dev. 9 (21): 2672–83. doi:10.1101/gad.9.21.2672. PMID7590244.
Takagaki Y, Manley JL (1994). "A polyadenylation factor subunit is the human homologue of the Drosophila suppressor of forked protein". Nature. 372 (6505): 471–4. Bibcode:1994Natur.372..471T. doi:10.1038/372471a0. PMID7984242.
Rüegsegger U, Beyer K, Keller W (1996). "Purification and characterization of human cleavage factor Im involved in the 3' end processing of messenger RNA precursors". J. Biol. Chem. 271 (11): 6107–13. doi:10.1074/jbc.271.11.6107. PMID8626397.
Kleiman FE, Manley JL (1999). "Functional interaction of BRCA1-associated BARD1 with polyadenylation factor CstF-50". Science. 285 (5433): 1576–9. doi:10.1126/science.285.5433.1576. PMID10477523.
Rush J, Moritz A, Lee KA, et al. (2005). "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells". Nat. Biotechnol. 23 (1): 94–101. doi:10.1038/nbt1046. PMID15592455.
Tsuzuki M, Wu W, Nishikawa H, et al. (2006). "A truncated splice variant of human BARD1 that lacks the RING finger and ankyrin repeats". Cancer Lett. 233 (1): 108–16. doi:10.1016/j.canlet.2005.03.012. PMID15878232.